Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer

Umberto Malapelle ¹, Natasha Leighl ², Alfredo Addeo ³

¹Department of Public Health, University of Naples Federico II, Naples, Italy.
²Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
³Oncology Unit, Geneva University Hospital, Geneva, Switzerland.
⁴Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
⁵Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
⁶National Cancer Institute, Cairo University, Cairo, Egypt.
⁷Institute of Pathology, Hannover Medical School, Hannover, Germany.
⁸Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
⁹Helmesely Cancer Center, Shaare Zedek Medical Center, Jerusalem, Israel.
¹⁰Division of Advanced Diagnostics, William Osler Health System, Brampton, ON, Canada.
¹¹Department of Pulmonary Diseases, Leiden University Medical Centre, Leiden, The Netherlands.
¹²UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, Spain.
¹³Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
¹⁴Merck Serono S.p.A., Rome, Italy.
¹⁵EMD Serono, Inc., Rockland, MA, USA.
¹⁶Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Medical System & Icahn School of Medicine, New York, NY, USA. christian.rolfo@mssm.edu.

⁰Department of Public Health, University of Naples Federico II, Naples, Italy.

British Journal of Cancer +

|

May 15, 2024

View abstract on PubMed

Summary

Standardized reporting of next-generation sequencing (NGS) results in non-small cell lung cancer is crucial. These best practice recommendations aim to improve NGS report interpretability for better patient treatment selection.

Area Of Science

Oncology
Genomics
Pathology

Background

Non-small cell lung cancer (NSCLC) is a complex disease requiring molecular characterization for effective treatment.
Next-generation sequencing (NGS) enables comprehensive profiling of NSCLC, identifying actionable targets for precision medicine.
Global adoption of NGS is hindered by a lack of standardized reporting guidelines.

Purpose Of The Study

To establish best practice recommendations for reporting NGS results in NSCLC.
To enhance the interpretability of NGS reports for clinicians.
To facilitate optimal patient selection for targeted therapies based on molecular profiles.

Main Methods

Development of recommendations based on roundtable discussions among pathologists and oncologists.
Review of existing guidelines for NGS utilization in solid and liquid biopsies.
Discussion of NGS workflows and report structures.

Main Results

Proposed best practice guidelines for reporting NGS results in NSCLC.
Emphasis on clear structure and comprehensive annotation of NGS reports.
Focus on ensuring full report interpretability for clinical decision-making.

Conclusions

Standardized NGS reporting is essential for the clinical management of NSCLC.
These recommendations aim to improve the consistency and utility of NGS reports.
Implementing these guidelines will support the selection of appropriate targeted therapies for NSCLC patients.